Success Metrics

Clinical Success Rate
100.0%

Based on 15 completed trials

Completion Rate
100%(15/15)
Active Trials
0(0%)
Results Posted
13%(2 trials)

Phase Distribution

Ph phase_2
11
73%
Ph phase_1
4
27%

Phase Distribution

4

Early Stage

11

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
4(26.7%)
Phase 2Efficacy & side effects
11(73.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

15 of 15 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(15)

Detailed Status

Completed15

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (26.7%)
Phase 211 (73.3%)

Trials by Status

completed15100%

Recent Activity

0 active trials
Showing 5 of 15
completedphase_2

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

NCT03536039
completedphase_1

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

NCT00419328
completedphase_2

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

NCT00483509
completedphase_1

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

NCT00305084
completedphase_2

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

NCT00484276
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT03536039Phase 2

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

Completed
NCT00419328Phase 1

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

Completed
NCT00483509Phase 2

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

Completed
NCT00305084Phase 1

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

Completed
NCT00484276Phase 2

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Completed
NCT00483080Phase 2

Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

Completed
NCT03804866Phase 2

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Completed
NCT01358084Phase 2

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

Completed
NCT00994097Phase 2

NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer

Completed
NCT00484432Phase 2

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

Completed
NCT01358071Phase 2

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Completed
NCT00878111Phase 1

Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour

Completed
NCT00675012Phase 2

NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

Completed
NCT00483093Phase 1

Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

Completed
NCT00484211Phase 2

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15